Wikipedia

Metabotropic glutamate receptor 1

(Redirected from GRM1A)

The glutamate receptor, metabotropic 1, also known as GRM1, is a human gene which encodes the metabotropic glutamate receptor 1 (mGluR1) protein.[5][6][7]

GRM1
Available structures
PDBOrtholog search: PDBe RCSB
Identifiers
AliasesGRM1, GPRC1A, MGLU1, MGLUR1, PPP1R85, SCAR13, glutamate metabotropic receptor 1, SCA44
External IDsOMIM: 604473; MGI: 1351338; HomoloGene: 649; GeneCards: GRM1; OMA:GRM1 - orthologs
Orthologs
SpeciesHumanMouse
Entrez

2911

14816

Ensembl

ENSG00000152822

ENSMUSG00000019828

UniProt

Q13255

P97772

RefSeq (mRNA)

NM_001114333
NM_016976

RefSeq (protein)

NP_001264993
NP_001264994
NP_001264995
NP_001264996

NP_001107805
NP_058672

Location (UCSC)Chr 6: 146.03 – 146.44 MbChr 10: 10.56 – 10.96 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

Function

edit

L-Glutamate is the major excitatory neurotransmitter in the central nervous system and activates both ionotropic and metabotropic glutamate receptors. Glutamatergic neurotransmission is involved in most aspects of normal brain function and can be perturbed in many neuropathologic conditions. The metabotropic glutamate receptors are a family of G protein-coupled receptors, that have been divided into 3 groups on the basis of sequence homology, putative signal transduction mechanisms, and pharmacologic properties. Group I, which includes GRM1 alongside GRM5, have been shown to activate phospholipase C. Group II includes GRM2 and GRM3 while Group III includes GRM4, GRM6, GRM7 and GRM8. Group II and III receptors are linked to the inhibition of the cyclic AMP cascade but differ in their agonist selectivities. Alternative splice variants of the GRM1 gene have been described but their full-length nature has not been determined.[5]

A possible connection has been suggested between mGluRs and neuromodulators, as mGluR1 antagonists block adrenergic receptor activation in neurons.[8]

Studies with knockout mice

edit

Mice lacking functional glutamate receptor 1 were reported in 1994. By homologous recombination mediated gene targeting those mice became deficient in mGlu receptor 1 protein. The mice did not show any basic anatomical changes in the brain but had impaired cerebellar long-term depression and hippocampal long-term potentiation. In addition they had impaired motor functions, characterized by impaired balance. In the Morris watermaze test, an assay for learning abilities, those mice needed significantly more time to successfully complete the task.[9]

Clinical significance

edit

Mutations in the GRM1 gene may contribute to melanoma susceptibility.[10] Antibodies against mGluR1 receptors cause cerebellar ataxia and impair long-term depression (LTDpathies) in the cerebellum.[11]

Ligands

edit

In addition to the orthosteric site (the site where the endogenous ligand glutamate binds) at least two distinct allosteric binding sites exist on the mGluR1.[12] A respectable number of potent and specific allosteric ligands – predominantly antagonists/inhibitors – has been developed in recent years, although no orthosteric subtype-selective ligands have yet been discovered (2008).[13]

  • JNJ-16259685: highly potent, selective non-competitive antagonist[14]
  • R-214,127 and [3H]-analog: high-affinity, selective allosteric inhibitor[15]
  • YM-202,074: high-affinity, selective allosteric antagonist[16]
  • YM-230,888: high-affinity, selective allosteric antagonist[17]
  • YM-298,198 and [3H]-analog: selective non-competitive antagonist[18]
  • FTIDC: highly potent and selective allosteric antagonist/inverse agonist[19]
  • A-841,720: potent non-competitive antagonist; minor hmGluR5 binding[20]
  • VU-71: potentiator[12]
  • Fluorinated 9H-xanthene-9-carboxylic acid oxazol-2-yl-amides: orally available PAMs[21]
  • Cyclothiazide: selective non-competitive antagonist of the mGluR1[22] (also AMPA potentiator and minor mGluR5 potentiator but not antagonist[23])
  • Riluzole : selective non-competitive antagonist[24]
  • Theanine : possible indirect inhibitor[25]
 
Chemical structures of mGluR1 selective ligands.

See also

edit

References

edit
  1. ^ a b c GRCh38: Ensembl release 89: ENSG00000152822 – Ensembl, May 2017
  2. ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000019828 – Ensembl, May 2017
  3. ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. ^ a b "Entrez Gene: GRM1 glutamate receptor, metabotropic 1".
  6. ^ Stephan D, Bon C, Holzwarth JA, Galvan M, Pruss RM (1996). "Human metabotropic glutamate receptor 1: mRNA distribution, chromosome localization and functional expression of two splice variants". Neuropharmacology. 35 (12): 1649–1660. doi:10.1016/S0028-3908(96)00108-6. PMID 9076744. S2CID 37222391.
  7. ^ Makoff AJ, Phillips T, Pilling C, Emson P (September 1997). "Expression of a novel splice variant of human mGluR1 in the cerebellum". NeuroReport. 8 (13): 2943–2947. doi:10.1097/00001756-199709080-00027. PMID 9376535. S2CID 28116484.
  8. ^ Smith RS, Weitz CJ, Araneda RC (August 2009). "Excitatory actions of noradrenaline and metabotropic glutamate receptor activation in granule cells of the accessory olfactory bulb". Journal of Neurophysiology. 102 (2): 1103–1114. doi:10.1152/jn.91093.2008. PMC 2724365. PMID 19474170.
  9. ^ Conquet F, Bashir ZI, Davies CH, Daniel H, Ferraguti F, Bordi F, et al. (November 1994). "Motor deficit and impairment of synaptic plasticity in mice lacking mGluR1". Nature. 372 (6503): 237–243. Bibcode:1994Natur.372..237C. doi:10.1038/372237a0. PMID 7969468. S2CID 4256888.
  10. ^ Ortiz P, Vanaclocha F, López-Bran E, Esquivias JI, López-Estebaranz JL, Martín-González M, et al. (November 2007). "Genetic analysis of the GRM1 gene in human melanoma susceptibility". European Journal of Human Genetics. 15 (11): 1176–1182. doi:10.1038/sj.ejhg.5201887. PMID 17609672.
  11. ^ Mitoma H, Honnorat J, Yamaguchi K, Manto M (December 2021). "LTDpathies: a Novel Clinical Concept". Cerebellum. 20 (6): 948–951. doi:10.1007/s12311-021-01259-2. PMC 8674158. PMID 33754326.
  12. ^ a b Hemstapat K, de Paulis T, Chen Y, Brady AE, Grover VK, Alagille D, et al. (August 2006). "A novel class of positive allosteric modulators of metabotropic glutamate receptor subtype 1 interact with a site distinct from that of negative allosteric modulators". Molecular Pharmacology. 70 (2): 616–626. doi:10.1124/mol.105.021857. PMID 16645124. S2CID 2719603.
  13. ^ based on a plain PubMed review
  14. ^ Lavreysen H, Wouters R, Bischoff F, Nóbrega Pereira S, Langlois X, Blokland S, et al. (December 2004). "JNJ16259685, a highly potent, selective and systemically active mGlu1 receptor antagonist". Neuropharmacology. 47 (7): 961–972. doi:10.1016/j.neuropharm.2004.08.007. PMID 15555631. S2CID 601322.
  15. ^ Lavreysen H, Janssen C, Bischoff F, Langlois X, Leysen JE, Lesage AS (May 2003). "[3H]R214127: a novel high-affinity radioligand for the mGlu1 receptor reveals a common binding site shared by multiple allosteric antagonists". Molecular Pharmacology. 63 (5): 1082–1093. doi:10.1124/mol.63.5.1082. PMID 12695537.
  16. ^ Kohara A, Takahashi M, Yatsugi S, Tamura S, Shitaka Y, Hayashibe S, et al. (January 2008). "Neuroprotective effects of the selective type 1 metabotropic glutamate receptor antagonist YM-202074 in rat stroke models". Brain Research. 1191: 168–179. doi:10.1016/j.brainres.2007.11.035. PMID 18164695. S2CID 3236484.
  17. ^ Kohara A, Nagakura Y, Kiso T, Toya T, Watabiki T, Tamura S, et al. (September 2007). "Antinociceptive profile of a selective metabotropic glutamate receptor 1 antagonist YM-230888 in chronic pain rodent models". European Journal of Pharmacology. 571 (1): 8–16. doi:10.1016/j.ejphar.2007.05.030. PMID 17597604.
  18. ^ Kohara A, Toya T, Tamura S, Watabiki T, Nagakura Y, Shitaka Y, et al. (October 2005). "Radioligand binding properties and pharmacological characterization of 6-amino-N-cyclohexyl-N,3-dimethylthiazolo[3,2-a]benzimidazole-2-carboxamide (YM-298198), a high-affinity, selective, and noncompetitive antagonist of metabotropic glutamate receptor type 1". The Journal of Pharmacology and Experimental Therapeutics. 315 (1): 163–169. doi:10.1124/jpet.105.087171. PMID 15976016. S2CID 15291494.
  19. ^ Suzuki G, Kimura T, Satow A, Kaneko N, Fukuda J, Hikichi H, et al. (June 2007). "Pharmacological characterization of a new, orally active and potent allosteric metabotropic glutamate receptor 1 antagonist, 4-[1-(2-fluoropyridin-3-yl)-5-methyl-1H-1,2,3-triazol-4-yl]-N-isopropyl-N-methyl-3,6-dihydropyridine-1(2H)-carboxamide (FTIDC)". The Journal of Pharmacology and Experimental Therapeutics. 321 (3): 1144–1153. doi:10.1124/jpet.106.116574. PMID 17360958. S2CID 10065500.
  20. ^ El-Kouhen O, Lehto SG, Pan JB, Chang R, Baker SJ, Zhong C, et al. (November 2006). "Blockade of mGluR1 receptor results in analgesia and disruption of motor and cognitive performances: effects of A-841720, a novel non-competitive mGluR1 receptor antagonist". British Journal of Pharmacology. 149 (6): 761–774. doi:10.1038/sj.bjp.0706877. PMC 2014656. PMID 17016515.
  21. ^ Vieira E, Huwyler J, Jolidon S, Knoflach F, Mutel V, Wichmann J (March 2009). "Fluorinated 9H-xanthene-9-carboxylic acid oxazol-2-yl-amides as potent, orally available mGlu1 receptor enhancers". Bioorganic & Medicinal Chemistry Letters. 19 (6): 1666–1669. doi:10.1016/j.bmcl.2009.01.108. PMID 19233648.
  22. ^ Surin A, Pshenichkin S, Grajkowska E, Surina E, Wroblewski JT (March 2007). "Cyclothiazide selectively inhibits mGluR1 receptors interacting with a common allosteric site for non-competitive antagonists". Neuropharmacology. 52 (3): 744–754. doi:10.1016/j.neuropharm.2006.09.018. PMC 1876747. PMID 17095021.
  23. ^ Surin A, Pshenichkin S, Grajkowska E, Surina E, Wroblewski JT (March 2007). "Cyclothiazide selectively inhibits mGluR1 receptors interacting with a common allosteric site for non-competitive antagonists". Neuropharmacology. 52 (3): 744–754. doi:10.1016/j.neuropharm.2006.09.018. PMC 1876747. PMID 17095021.
  24. ^ Lemieszek MK, Stepulak A, Sawa-Wejksza K, Czerwonka A, Ikonomidou C, Rzeski W (2018). "Riluzole Inhibits Proliferation, Migration and Cell Cycle Progression and Induces Apoptosis in Tumor Cells of Various Origins". Anti-Cancer Agents in Medicinal Chemistry. 18 (4): 565–572. doi:10.2174/1871520618666180228152713. PMID 29493465. S2CID 3605151.
  25. ^ Nagasawa K, Aoki H, Yasuda E, Nagai K, Shimohama S, Fujimoto S (July 2004). "Possible involvement of group I mGluRs in neuroprotective effect of theanine". Biochemical and Biophysical Research Communications. 320 (1): 116–122. doi:10.1016/j.bbrc.2004.05.143. PMID 15207710.

Further reading

edit

This article incorporates text from the United States National Library of Medicine, which is in the public domain.


edit
Retrieved from "https://en.wikipedia.org/w/index.php?title=Metabotropic_glutamate_receptor_1&oldid=1246759857"